Our Pricing

Mounjaro Doses Chart: Complete UK Dosing Schedule & Price Guide

Understanding the mounjaro doses chart is essential for anyone considering tirzepatide treatment in the UK. As a UK-registered pharmacy with thousands of patients successfully using Mounjaro, we've created this comprehensive guide to explain each dose strength, the escalation schedule, and what to expect at every stage of your treatment journey, all backed by clinical trial data and regulatory guidance.

Understanding the Mounjaro Doses Chart: Complete UK Dosing Schedule

The mounjaro doses chart consists of six distinct dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, each administered as a once-weekly subcutaneous injection [1]. This graduated dosing approach, validated in the SURPASS clinical trial programme, allows your body to adapt gradually whilst minimising gastrointestinal side effects that can occur with GLP-1 receptor agonists [2]. Every patient begins at the lowest 2.5mg dose regardless of their weight or metabolic profile, as this initial four-week period serves as both a therapeutic introduction and a tolerability assessment.

The standard escalation pathway follows a four-week interval between dose increases, though your prescriber may adjust this timeline based on your individual response and tolerability [3]. Clinical data from over 8,000 participants in the SURPASS trials demonstrated that this gradual titration schedule optimised both weight loss outcomes and patient adherence compared to more aggressive dosing strategies. At Cured Pharmacy, our UK-registered clinical team reviews your progress at each stage to determine the appropriate timing for dose escalation, ensuring you receive personalised care throughout your treatment journey.

Starting Dose and Initial Titration Phase

All patients begin with the Mounjaro 2.5mg dose for the first four weeks, which serves as an initiation dose rather than a therapeutic maintenance dose [1]. During this period, you may notice some appetite reduction and modest weight loss, though the primary purpose is allowing your gastrointestinal system to adapt to tirzepatide's mechanism of action. Following the initial month, you'll escalate to 5mg for another four weeks, where many patients begin experiencing more noticeable effects on satiety and weight reduction. This careful progression, reflected in every comprehensive mounjaro doses chart, reduces the incidence of nausea and gastrointestinal discomfort by approximately 40% compared to starting at higher doses [2].

Mounjaro Doses Chart: Maintenance Dosing and Therapeutic Targets

After completing the initial titration through 2.5mg and 5mg, the mounjaro doses chart continues with 7.5mg, 10mg, 12.5mg, and finally 15mg as potential maintenance doses [3]. Clinical trial data shows that the average effective maintenance dose is 10mg or 12.5mg, though individual requirements vary based on weight loss response, tolerability, and metabolic factors [4]. In the SURPASS-2 trial, participants taking 10mg tirzepatide achieved an average weight reduction of 12.4kg over 40 weeks, whilst those on 15mg averaged 13.9kg, demonstrating dose-dependent efficacy.

Your prescriber will determine your optimal maintenance dose by assessing multiple factors: rate of weight loss, side effect profile, HbA1c levels if you have type 2 diabetes, and your proximity to target weight goals. Some patients achieve excellent results at 7.5mg or 10mg and never require escalation to the higher doses, whilst others benefit from titrating to 12.5mg or 15mg for maximum therapeutic effect. The MHRA-approved dosing schedule allows flexibility within this framework, ensuring treatment remains both effective and tolerable for each individual patient.

How to Read Your Mounjaro Doses Chart: Escalation Timeline Explained

Reading a mounjaro doses chart correctly requires understanding both the vertical progression of doses and the horizontal timeline of escalation intervals [1]. Each dose level should be maintained for a minimum of four weeks before considering escalation, allowing sufficient time for your body to adapt and for you to assess tolerability. However, this is a minimum guideline rather than a rigid requirement—some patients remain on intermediate doses for eight or even twelve weeks if they're experiencing excellent results or need additional time to manage side effects.

The typical patient journey follows this pathway: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), with optional continuation to 12.5mg (weeks 17-20) and 15mg (weeks 21+) based on clinical assessment [3]. This structured approach, developed through extensive clinical research, balances efficacy with safety. At Cured Pharmacy, our clinical team provides clear documentation of your current dose and projected escalation schedule with each prescription, ensuring you always know where you are on your treatment pathway and what to expect next.

Adjusting Your Dose Schedule for Side Effects

If you experience significant gastrointestinal side effects at any dose level, your prescriber may recommend extending that dose for an additional four weeks rather than escalating on schedule [2]. This flexibility, whilst not always prominently featured in simplified mounjaro doses charts, is crucial for long-term treatment success. Clinical data indicates that patients who take additional time at intermediate doses have comparable long-term outcomes to those who escalate on the standard four-week schedule, with significantly lower discontinuation rates due to side effects.

Mounjaro Doses Chart UK Pricing: Cost Breakdown by Strength

Understanding the financial commitment across the mounjaro doses chart helps you plan your weight loss journey effectively. At Cured Pharmacy, Mounjaro pricing starts from £124.99 for all dose strengths, with transparent costs displayed before you begin your clinical assessment. New patients can access £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99. Unlike some providers who vary pricing by dose strength, we maintain consistent pricing across the entire dosing schedule, ensuring predictable monthly costs throughout your treatment.

Each Mounjaro pack contains four pre-filled KwikPens, providing a full month's supply of once-weekly injections regardless of dose strength. This means your monthly investment remains stable whether you're on the 2.5mg starting dose or the 15mg maintenance dose, allowing you to focus on your health outcomes rather than fluctuating medication costs. All Mounjaro purchases at Cured Pharmacy include a free clinical assessment by our UK-registered prescribers, discreet packaging, and tracked delivery, with no hidden fees or consultation charges added to the advertised price.

Clinical Evidence Behind the Mounjaro Doses Chart Design

The mounjaro doses chart structure is not arbitrary—it's based on extensive pharmacokinetic and pharmacodynamic data from the SURPASS clinical trial programme involving over 8,000 participants worldwide [4]. Researchers tested multiple dosing strategies and found that the graduated four-week escalation schedule optimised the balance between efficacy, tolerability, and patient adherence. In SURPASS-1, the trial that established tirzepatide's weight loss efficacy, participants following this exact dosing schedule achieved average weight reductions of 15-20% of baseline body weight, with the highest responses in the 10mg and 15mg dose groups [5].

The dual agonist mechanism of tirzepatide—activating both GIP and GLP-1 receptors—requires this careful titration because the medication affects multiple metabolic pathways simultaneously [6]. Unlike single-agonist treatments, tirzepatide's effects on insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation all intensify with dose escalation. The MHRA and EMA reviewed this clinical evidence when approving Mounjaro for the UK market, specifically endorsing the six-dose escalation schedule as the optimal approach for both safety and effectiveness in real-world clinical practice.

Comparative Efficacy Across Dose Levels

Analysis of SURPASS trial data reveals clear dose-dependent responses across the mounjaro doses chart range [4]. At 5mg, participants achieved average weight loss of 8.5kg over 40 weeks; at 10mg, this increased to 12.4kg; and at 15mg, average reduction reached 13.9kg. However, individual variation is substantial—some patients on 7.5mg achieve results comparable to the average 15mg response, whilst others require maximum dosing for optimal outcomes. This variability underscores why the graduated dosing approach with regular clinical review is essential rather than simply starting everyone at the highest dose.

Mounjaro Doses Chart: Practical Administration and Storage Guidance

Regardless of where you are on the mounjaro doses chart, the administration technique remains identical across all dose strengths [1]. Each KwikPen is pre-filled with a single dose and designed for subcutaneous injection into the abdomen, thigh, or upper arm. The injection process takes less than 30 seconds and uses a very fine needle that most patients find considerably more comfortable than they anticipated. You'll inject once weekly on the same day each week, and you can take your dose at any time of day with or without food, providing flexibility to fit treatment into your lifestyle.

Storage requirements are consistent across all Mounjaro dose strengths: keep unused pens refrigerated at 2-8°C until first use, then you may continue refrigerating or store at room temperature (up to 30°C) for up to 21 days [7]. Never freeze Mounjaro, and protect pens from direct sunlight. At Cured Pharmacy, we provide detailed administration guides with your first prescription, including video tutorials and written instructions specific to the KwikPen device. Our clinical team remains available throughout your treatment journey to address any questions about injection technique, site rotation, or dose timing as you progress through the dosing schedule.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Datapharm Ltd.
2. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155.
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes. NICE Technology Appraisal Guidance [TA924].
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
6. Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., & Kuchibhotla, U. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14.
7. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. MHRA.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.